Copy

It has been a rewarding summer for Novateur and its clients and portfolio investment companies! Despite the heat and the vacation season, this summer has seen a flurry of notable activities across the Life Sciences.

We are excited to announce new Novateur services as well as to celebrate the success of Novateur clients and our investment portfolio companies in closing deals, partnerships, and investments. Congratulations to IRICoR, Feldan Therapeutics, Navigo Proteins, MetaOptima, Vasomune, Immune BioSolutions and AIT Therapeutics.

In our industry review blog, we discuss a confluence of positive events that have created a perfect storm and the reasons why we encourage our clients to close partnerships and financings as quickly as possible...

read more
CLIENT DEALS, PARTNERSHIPS & INVESTMENTS

We are delighted to celebrate the success of our clients and portfolio investment companies.
Novateur Investment Portfolio

Iricor

Our valued client, IRICoR and Université de Montréal entering into a Research Collaboration with AbbVie, pharmaceutical division of Abbot, to Discover Tumor-Specific Neoantigens. A shout out to our friends Steven Klein and Drs. Perreault’s and Thibault’s for their first pharma deal.

FOR MORE INFO CLICK HERE

FELDAN THERAPEUTICS

Our valued client and investment portfolio company, Feldan Therapeutics, announces a license agreement to develop next-generation NK cells for immunotherapy using Feldan Shuttle technology with GC LabCell. Congrats to the dedicated team at Feldan, especially the founder, Dr. Francois-Thomas Michaud.

FOR MORE INFO CLICK HERE

NAVIGO PROTEINS

Our valued client, Navigo Proteins, announces co-development agreement with Repligen (NASDAQ:RGEN) for exclusive co-development of next-generation Affinity Ligands. Congrats to Drs. Afflerbach and Haupts.

FOR MORE INFO CLICK HERE

METAOPTIMA

Our investment portfolio digital health company, MetaOptima, raises $8.6 M CAD Series A financing from a group of Australian VCs. A shout out to co-founders Dr. Maryam Sadeghi and Majid Razmara.

FOR MORE INFO CLICK HERE

Immune Biosolutions

Our valued client Immune Biosolutions has entered into a research collaboration and license agreement with Johnson & Johnson Innovation to identify and develop therapeutic antibodies for multiple targets. Well done Frédéric Leduc and the team at Immune Biosolutions for completing your first large pharma partnership.

FOR MORE INFO CLICK HERE

VASOMUNE

Our valued client Vasomune, a MaRS Innovation company, has signed a multimillion-dollar deal with AnGes, Inc. for the development and commercialization of therapeutics treating diseases associated with blood vessel dysfunction and destabilization. Congratulations to the Vasomune and MaRS Innovation team, especially Parimal Nathwani for a job well done.

FOR MORE INFO CLICK HERE

AIT

Our valued client and investment portfolio company, AIT Therapeutics, has announced $20 million common stock purchase agreement with institutional investor, Lincoln Park Capital Fund.

FOR MORE INFO CLICK HERE

NOVATEUR’S 
NEW SERVICES


Novateur’s goal is to accelerate planning, execution, and growth for its client across Life Sciences and Healthcare and ultimately improving patients’ lives. With a proven track record to bring the best executive talent together, Novateur has created a seamless integration of services across a diverse portfolio.
Novateur Team

Please welcome our new executives:

Business Development Executive Advisory Suite

Working with clients to prepare client’s presentations, engage pharmaceutical partners, negotiate and execute licensing.

Dr. Anne Assmus
Global Lead BD/Platform and Therapeutics

(Affimed, Immatics, MorphoSys, Novozymes)

Jack Tupman
Senior Pharma Business Development Advisor

(Previously VP Business Development at Eli Lilly)

venture Capital Executive Advisory Suite

Sourcing and developing financing strategies and financial plans for venture capital investment engagements.

Eric Zimmerman
Head Global Venture Capital Financing

(6 Dimensions Capital, Excel Venture Management, Santé Ventures, Sofinnova Ventures)

HUMAN RESOURCES Executive Advisory Suite

Executive search and talent development advisory

Kataneh Sherkat
Head Talent & Executive Search 

(WMC, KASA Coaching, Odgers Berndtson, Deloitte, CIBC)

Digital Health Executive Advisory Suite

Inaugural Advisory Suite for Novateur’s growing digital health portfolio to provide Healthcare Strategy and Investment advice.

Betsabeh Madani
Senior Advisor, Digital Health

(Auxterra, Cerner, Equicare Health, Innovation Boulevard, BCG)

CLINICAL DEVELOPMENT EXECUTIVE Advisory Suite

Mayme Wong, PhD
Clinical Advisory Lead

(Previously Clinical Scientist Drugs & Devices Eli Lilly)

Read the new blog post by Dr. Mayme Wong: 
Clinical Evaluation Reports for EU-Marketed Medical Devices – A Summary of the Regulatory Guidance

Following the June 2016 release of the new MEDDEV 2.7/1, revision 4 guidance (Rev 4), manufacturers of CE-marked medical devices are scrambling to maintain compliance. Clinical evaluation is necessary for the initial CE-marking of new devices, as well as for devices that have been marketed for years.  Manufacturers are required to provide sufficient evidence to show conformity of the medical device to the Essential Requirements, and its performance and safety when used clinically according to the instructions for use. Clinical Evaluation Reports (CERs) must be created during device development and updated periodically throughout the marketed lifetime of the device in the EU.  This summary outlines the major aspects of this regulatory requirement.

read more




UPCOMING
EVENTS

 


LifeSciences BC Blakes Breakfast Speaking Event

September 27, 2018 - Vancouver, BC

The Blakes Breakfast Speaking Series is LifeSciences BC's longest-standing event series and one of the most popular. Held four times a year, these breakfasts include presentations by local, national and multinational life science companies and typically attract a cross-section of approximately 60 of our life sciences community members. The Breakfast Speaking Series is proudly presented by Blake, Cassels & Graydon LLP.
 
Keynote speaker:
Dr. Arpita Maiti, Senior Director, External Science & Innovation (ES&I), Inflammation & Immunology and Microbiome at Pfizer Boston

Speakers:
Tamer Mohamed, CEO at Aspect Biosystems
Michael Gallo, President of Innovative Targeting Solutions

MORE INFO


LifeSciences BC Investor Summit 2018 presented by Lumira Ventures

October 25, 2018 - Vancouver, BC

LifeSciences BC and Lumira Ventures are proud to partner in presenting the Investor Summit 2018 to be held in Vancouver on Thursday, October 25 at the Fairmont Pacific Rim. The Investor Summit will bring together stakeholders in the healthcare innovation ecosystem for an exciting day of company pitches. Entrepreneurs will tell their stories and get feedback and engagement from a wide range of investor stakeholders including; angel investors, venture capital, corporate ventures and funding foundations.

MORE INFO





RECENT
EVENTS

 

VANTEC MEETING LIFE 
SCIENCES ANGEL NETWORK

Annual Life Sciences themed investor meeting where VANTEC Angel Network invites and selects BC's most promising Seed and Series A companies in the Medical Device, Pharma/Biotech, Digital Health, and Health IT sectors. Companies from across BC were invited to apply to pitch and we welcome investors referrals of their portfolio companies. 

Companies who were upvoted by the investors during the June 13 meeting are invited to participate in the upcoming Cascadia Venture Forum (CVF) to be held during Fall 2018 in Seattle.

MORE INFO

Ali Ardakani, Founder & Managing Director of Novateur and Vice Chair, Board of Directors of LifeSciences BC, was moderating the panel Corporate Partnership: Pitfalls and Opportunities.

Panelists:
Jennifer J. Hamilton, PhD, Senior Director, Johnson & Johnson - New Ventures (Canada);
Janet Grove, Managing Partner, Norton Rose Fulbright (Vancouver);
Lesley Esford, President, LifeSciences BC; 
Jonathon Jafari, Senior Director, Business Development at CDRD (Centre for Drug Research & Development)

BIO INTERNATIONAL 
CONVENTION 2018

The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. 

BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

MORE INFO

Ali Ardakani, Founder & Managing Director of Novateur and Vice Chair, Board of Directors of LifeSciences BC; Dr. Lesley Esford, President of the LifeSciences BC - in the Canada pavilion of the BIO 2018 International Convention. 
Canadian delegation was among the largest international delegations at BIO 2018.

Ali Ardakani, Founder & Managing Director of Novateur and Vice Chair, Board of Directors of LifeSciences BC, gave welcoming remarks on behalf of LifeSciences BC at the Massachusetts’s Lessons for Venture Capital Financing Panel at BIO 2018 on June 4, 2018

Panelists:
Dr. Paulina Hill, Principal, Polaris Partners;
Dr. David Poon, Executive Director, External R&D and Alliances, Zymeworks Inc.;
Dr. Jens Eckstein, President, SR One;
Martin Leblanc, President and CEO, Caprion Biosciences Inc.; Scott Requadt, Managing Director, Clarus Ventures;
Panel moderated by Gerry Brunk, Managing Director, Lumira Capital

Ali Ardakani, Founder & Managing Director of Novateur and Vice Chair, Board of Directors of LifeSciences BC; Ella Korets-Smith, Executive Director, TO Health!; Frank Béraud, Chief Executive Officer, Montréal InVivo - at the Massachusetts’s Lessons for Venture Capital Financing Panel, BIO 2018, Boston





CLIENT
TESTIMONIALS

 

"Novateur team were able to help us address a number of critical commercial and regulatory issues facing one of our start-up companies working in the cell therapy field. Novateur delivered actionable recommendations that allowed us to deliver a clear and complete business plan to potential investors."

— Steven J. Klein, PhD, MBA
Vice President, Business Development, IRICoR

"Novateur team has been of a tremendous help for us to achieve a transition from a technology company to a therapeutic company. They are a deeply experienced team and it is easy and fun working with them… they genuinely care about your project."

— Dr. Francois-Thomas Michaud
CEO, Feldan Therapeutics

"Novateur’s team demonstrated the deep clinical and regulatory knowledge required for our start-up with the flexibility of engagement to drive success for our company."

— Parimal Nathwani
President & CEO, Vasomune Therapeutics

"The Novateur Ventures’ team guided us to the next level, bringing knowledge, experience and credibility to our team. Simply put, it was like having a world class scientific advisory board, BD team, drug development team simultaneously!"

— Dr. Frederic Leduc
Co-founder & CEO, Immune Biosolutions

testimonials
+1 844 200 6682
Toll free USA & Canada
 
download our presentation
Copyright © 2018 Novateur Ventures Inc., All rights reserved.


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

Email Marketing Powered by Mailchimp